Conference Service Mandl

abstract: Completing the sequence of human and other genomes will soon elucidate the precise location and base sequence of every gene in a reference genome. This reference allows for rapid characterization of polymorphisms across populations. It also enables molecular fingerprinting technologies to permit identification of the precursors and consequences of normal and pathological changes in gene expression. The challenge facing current biological research is effective matching of the tool to the target. Learn from seasoned and savvy researchers who share their experience and of challenges piecing together the biological puzzle of health and disease at Cambridge Healthtech Institute’s 4th Annual Genomic Tools: Targeting the Missing Links between Health and Disease. www.healthtech.com

abstract: As new sequencing platforms are capable of generating gigabytes of data in a single sequence run - leading to terabytes of data in an experiment; data storage, transfer, and analysis will unquestionably be the rate limiting steps in turning the new sequence data into knowledge. CHI’s Inaugural Next-Generation Sequencing Data Analysis convenes engineers who are developing the sequencing platforms, biological researchers who are designing and running the experiments, biosatiations who are analyzing and interpreting the data, and software developers who are managing and storing the data. Each specialty provides perspectives and must be integrated into a cohesive, comprehensive team to decipher the sequencing data deluge. www.healthtech.com

abstract: Gene Acres is a one-day facilities conference featuring timely analysis of issues by professionals from multiple perspectives. From facilities design to security, and from regulatory certification to international operations, Gene Acres conference provides insights into the challenges faced by life science companies every day. A closing reception will provide a perfect opportunity to network with your peers.

* What: 16th Annual Gene Acres Conference

* When: 8:30am - 5:30pm, Wednesday, September 24, 2008

* Where: South San Francisco Conference Center, 255 South Airport Blvd., South San Francisco, CA. Directions.

* Attire: Business Attire Suggested

* Present at the 16th Annual Gene Acres Conference - Submit a Session!

* Conference Sponsorship Opportunities

* Media Registration

abstract: Genomic research has become a discipline to be integrated with clinical medicine. Currently, genomic technologies allow for the simultaneous quantification of gene activity in tissues/cells from patients. Will these genomic technologies make it possible to develop personalized medicine leading to a more accurate diagnosis and prognosis for every patient and subsequently a tailored treatment strategy? With the addition and linkage of clinical parameters disparate data points are created. All agree data integration is crucial. Join innovators from technological platform development, biostatistical analysis, biological, pharmaceutical, and clinical research as they share their experiences and insights for Integrative Data Analysis: Is Personalized Medicine at Hand? www.healthtech.com

abstract: Next-Generation sequencing is alive, thriving, and driving discovery. As costs come down and ease increases these new massively parallel high-throughput sequencing platforms are infiltrating multiple aspects of traditional biological research. However, each next generation sequencing platform best lends itself to specific sequencing goals. Cambridge Healthtech Institute’s Exploring Next Generation Sequencing offers an unparalleled opportunity to compare and contrast these next generation sequencing platforms to best suit your research needs. www.healthtech.com

abstract: •Fourth Annual Genomic Biomarkers •Sixth Annual Protein Biomarkers •Ninth Annual Metabolic Biomarkers www.BiomarkerDiscoverySummit.com

abstract: The TriMark Molecular Diagnostics Conference 2008 has been organized to provide a critical examination of the molecular diagnostics industry, as well as insight from key industry leaders concerning cutting edge molecular diagnostics technology, structuring mutually beneficial deals and the molecular diagnostics industry’s impact on the field of in vitro diagnostics. This conference will also provide an integral forum for leaders in molecular diagnostics, in vitro diagnostics and laboratories to share ideas, network with other delegates and advance understanding of the potential of new molecular diagnostics technologies.

abstract: Generating and interpreting molecular interaction data is hard enough, however, properly applying that information to aid drug discovery and development is an even bigger challenge. Are you aware of the multitude of molecular interactions that affect biotherapeutics? Gain a better understanding of PK Assay strategies to support non-clinical and clinical studies.Which drug species should be measured and why? Could you use tools and strategies for development of novel Antibody-Drug Conjugates (ADCs)? Join us to discuss some of the fundamental biochemical underpinnings of bioanalytical assays, as well as to hear case studies describing assays and how they addressed particular bioanalytical questions.

*Understand and Apply Molecular Interactions

*Current PK Assay Strategies

*Bioanalytical Strategies for Antibody-Drug Conjugates

*Assessment of Fc Functionality

This exciting premiere event is the first time all of these critical componen

abstract: The American Biological Safety Association (ABSA) was founded in 1984 to promote biosafety as a scientific discipline and serve the growing needs of biosafety professionals throughout the world. Its goals are to provide a professional association that represents the interests and needs of practitioners of biological safety, and to provide a forum for the continued and timely exchange of biosafety in formation.

ABSA accomplishes these goals by publishing and distributing a quarterly journal, Applied Biosafety and a number of other biosafety publications. ABSA also conducts an annual Biological Safety Conference to keep members informed of current biosafety issues and regulatory initiatives. The conference is preceded by a selection of biosafety courses geared at the beginner and advanced levels. In addition, ABSA produces an annual membership directory to stimulate networking.

ABSA offers a registration (Registered Biosafety Professional) and certification (Certifi

abstract: The TriMark Stem Cell Conference 2008 has been organized to provide a critical examination of the stem cell industry, as well as insight from key industry leaders concerning cutting edge stem cell technology, structuring mutually beneficial deals and the stem cell industry’s impact on the field of regenerative medicine and drug discovery. This conference will also provide an integral forum for leaders in stem cell research centers and laboratories to share ideas, network with other delegates and advance understanding of the potential of stem cell technology.

abstract: The greater New York metropolitan area has become a leading center for research on chromosome biology and function, as well as for research at the interface between chromosome integrity and cell cycle regulation. The Genome Integrity Discussion Group meets four to five times each year and provides an opportunity for researchers active in this area to exchange ideas and form research collaborations.

abstract: A workshop on the science and practical issues of small animal imaging will be held at Stanford on November 5-8, 2008. The workshop will cover new commercially available small animal imaging systems (optical, radionuclide, x-ray, magnetic resonance, and ultrasound) and how researchers use these small animal imaging systems to study the molecular basis of disease noninvasively and aid in the discovery, development, and monitoring of novel molecular-based treatments.

abstract: Welcome to the Nucleic Acid Diagnostics & Therapeutics Summit. This inaugural summit will be be held in Boston, MA immediately prior to the annual RNAi World Congress, which will address the latest research in RNAi and microRNA research. In contrast the DxRx Summit will be attended by investors, corporate management, business leaders, legal & regulatory advisors, clinical trial CROs and others who are interested in the diagnostic and therapeutic applications of DNA, RNAi, microRNAs, and antisense technology. Registered delegates will also be eligible to attend a half-day interactive business tutorial on the market and business landscape for diagnostics and therapeutics based on RNAi and microRNAs hosted by Enal Razvi, PhD. Agenda Topics to include: Reviews of Company Pipelines Clinical Trial Status of Nucleic Acid-Based Therapeutics Patent Status of Nucleic Acid-Based Diagnostics and Therapeutics Nucleic Acid Drug Delivery microRNAs as Diagnostics and Therapeutic Entities Nucleic Acid Biomarkers for Personalized Medicine Reimbursement and Regulatory Landscape Investor Attitudes to this Sector Emerging Company Showcase Confirmed Speakers: Dr Patrick Y. Lu, President and CEO, Sirnaomics Dr Dmitry Samarsky, VP Technology Development, RXi Pharmaceuticals Dr James Hamilton, CEO, Calando Pharmaceuticals Prof James G Patton, Vanderbilt University Jeffery Vick, CEO, Silence Therapeutics Dr Nobuyoshi Kosaka, National Cancer Center Research Institute, Tokyo Dr Nicolay Ferrari, Director of Pharmacology, Topigen Dr Søren Tulstrup, CEO, Santaris Pharma Dr William Marshall, President and CEO, Miragen Therapeutics

abstract: Welcome to the 3rd annual RNAi World Congress. This year's event will be held in Boston, home to many of the world's top institutions engaged in gene silencing research. Keynote Speakers: Phillip Zamore, Professor, University of Massachusetts Medical School George Calin, Associate Professor University of Texas M D Anderson Cancer Centre David Root, Director, RNAi Platform and Project Leader, The RNAi Consortium Broad Institute of MIT and Harvard Agenda Topics to include: Target Discovery and Validation Transfection in vivo RNAi siRNA library screens microRNAs in Disease Biology Stem Cell Biology Diagnostics Virology Biogenesis Development

abstract: BIO is the world's largest biotechnology organization, providing advocacy, business development and communications services for more than 1,150 members worldwide. Our mission is to be the champion of biotechnology and the advocate for our member organizations—both large and small.

BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. We also represent state and regional biotech associations, service providers to the industry

abstract: The American Biological Safety Association (ABSA) was founded in 1984 to promote biosafety as a scientific discipline and serve the growing needs of biosafety professionals throughout the world. Its goals are to provide a professional association that represents the interests and needs of practitioners of biological safety, and to provide a forum for the continued and timely exchange of biosafety in formation.

ABSA accomplishes these goals by publishing and distributing a quarterly journal, Applied Biosafety and a number of other biosafety publications. ABSA also conducts an annual Biological Safety Conference to keep members informed of current biosafety issues and regulatory initiatives. The conference is preceded by a selection of biosafety courses geared at the beginner and advanced levels. In addition, ABSA produces an annual membership directory to stimulate networking.

ABSA offers a registration (Registered Biosafety Professional) and certification (Certifi